TheraPsil, a Canadian coalition for psilocybin therapy legalization, together with the U.K. independent foundation Drug Science, has launched Project Solace.
The goal is to gather data to better inform patients about the development of regulated psilocybin products. That way it can document clinical effectiveness, safety, clinician and patient-reported outcomes in those receiving medical psilocybin-assisted psychotherapy via the Canadian Special Access Programme (SAP) or under exemptions that authorize psilocybin possession.
Project Solace also hopes to expand legal access to medical psilocybin for Canadian patients suffering from end-of-life distress, Major Depressive Disorder (MDD) or other mental health conditions for which traditional treatment options have failed.
Regarding the potential patient benefit the SAP holds, Drug Science founder David Nutt expressed that it could be “a life-changing opportunity to receive psilocybin-assisted psychotherapy from a team of trained medical professionals.”
The clinical trial procedure …